Based on the Foghorn Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Foghorn Therapeutics Inc is USD 12.50 over the next 12 months. Foghorn Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Foghorn Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Foghorn Therapeutics Inc’s stock price was USD 3.44. Foghorn Therapeutics Inc’s stock price has changed by -2.27% over the past week, -26.34% over the past month and -51.55% over the last year.
No recent analyst target price found for Foghorn Therapeutics Inc
No recent average analyst rating found for Foghorn Therapeutics Inc
Company Overview Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Read Less
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Co...Read More
Frequently Asked Questions About Foghorn Therapeutics Inc (FHTX) Stock
Based on ratings from 3 analysts Foghorn Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on FHTX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for FHTX is USD 12.50 over the next 12 months. The maximum analyst target price is USD 14 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on FHTX's stock to indicate if its overvalued.
The last closing price of FHTX's stock was USD 3.44.
The most recent market capitalization for FHTX is USD 0.20B.
Based on targets from 3 analysts, the average taret price for FHTX is projected at USD 12.50 over the next 12 months.
This means that FHTX's stock price may go up by +263.37% over the next 12 months.
We can't find any ETFs which contains Foghorn Therapeutics Inc's stock.
As per our most recent records Foghorn Therapeutics Inc has 112 Employees.
Foghorn Therapeutics Inc's registered address is 500 Technology Square, Cambridge, MA, United States, 02139.
You can get more information about it from Foghorn Therapeutics Inc's website at https://foghorntx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Foghorn Therapeutics Inc (FHTX) Stock
Based on ratings from 3 analysts Foghorn Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on FHTX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for FHTX is USD 12.50 over the next 12 months. The maximum analyst target price is USD 14 while the minimum anlayst target price is USD 10.
Unfortunately we do not have enough data on FHTX's stock to indicate if its overvalued.
The last closing price of FHTX's stock was USD 3.44.
The most recent market capitalization for FHTX is USD 0.20B.
Based on targets from 3 analysts, the average taret price for FHTX is projected at USD 12.50 over the next 12 months.
This means that FHTX's stock price may go up by +263.37% over the next 12 months.
We can't find any ETFs which contains Foghorn Therapeutics Inc's stock.
As per our most recent records Foghorn Therapeutics Inc has 112 Employees.
Foghorn Therapeutics Inc's registered address is 500 Technology Square, Cambridge, MA, United States, 02139.
You can get more information about it from Foghorn Therapeutics Inc's website at https://foghorntx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for FHTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
